GlassScriptPhysician profile
Sarah A Mayfield
NPI 1992732820
$4,837.40
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $609 · 2021: $1,001 · 2022: $1,032 · 2023: $1,210 · 2024: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,445.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,297.79 | 2019-2024 | |
| Novo Nordisk INC | $597.03 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $544.30 | 2019-2023 | Pediarix, Bexsero, Shingrix |
| Lilly USA, LLC | $525.33 | 2019-2023 | Mounjaro, Trulicity, Emgality |
| Pfizer INC. | $277.72 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $210.74 | 2019-2023 | Flumist Quadrivalent |
| Corium, LLC | $192.06 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $170.82 | 2021-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $142.59 | 2019-2023 | Jornay Pm |
| Sanofi Pasteur INC. | $126.33 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.25 | 2020-2021 | |
| Cranial Technologies, INC | $70.86 | 2019-2022 | |
| Allergan, INC. | $62.44 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $61.93 | 2019-2021 | |
| Mannkind Corporation | $42.02 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $40.32 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $38.84 | 2021-2022 | |
| Seqirus USA INC | $36.03 | 2021-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Siemens Medical Solutions USA, INC. | $29.02 | 2021 | |
| Kyowa Kirin, INC. | $27.51 | 2023 | Crysvita |
| Amgen INC. | $27.21 | 2020-2023 | Repatha |
| Teva Pharmaceuticals USA, INC. | $24.06 | 2021 | |
| Sobi, INC | $21.12 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.96 | 2024 | |
| Idorsia Pharmaceuticals US INC | $20.30 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.57 | 2022 | |
| Abbott Laboratories | $19.25 | 2022 | |
| Medtronic Vascular, INC. | $18.96 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.38 | 2024 | Nuzyra |
| Kaleo, INC. | $13.56 | 2020 | |
| Alfasigma USA, INC. | $13.53 | 2021 | |
| Shire North American Group INC | $12.79 | 2019 | |
| Medtronic, INC. | $12.64 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Mayfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.